scholarly journals Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Yinhua Wang ◽  
Xiuhua Shi ◽  
Qinghua Qi ◽  
Bin Ye ◽  
Zhaoling Zou
Keyword(s):  
Tumor Markers ◽  
Adverse Reactions ◽  
Advanced Nsclc ◽  
Combined Treatment ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Serum Tumor Markers ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

Objective. To explore the safety of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced non-small-cell lung cancer (NSCLC) and their effect on serum tumor markers. Methods. 88 patients with advanced NSCLC treated in the Oncology Department of our hospital from December 2018 to December 2019 were selected as research subjects and randomly and equally split into the single treatment group (STG) and combined treatment group (CTG). The levels of serum tumor markers after treatment were detected in both groups, and the incidence of adverse reactions during treatment was recorded. Results. Compared with the STG, CTG achieved obviously higher total effective rate ( P  < 0.05), lower total incidence of adverse reactions ( P  < 0.05), lower levels of serum tumor markers and average CFS score ( P  < 0.001), and higher average KPS score ( P  < 0.001). Conclusion. Application of anlotinib capsules combined with the PD-1 inhibitor (camrelizumab) in the third-line treatment of advanced NSCLC can effectively reduce the levels of serum tumor markers and cancer fatigue degree of patients, with a better effect than that of simple anlotinib treatment. In addition, further research of the combined treatment is helpful to establish a better therapeutic regimen for patients with advanced NSCLC.

scholarly journals Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience

2021 ◽  
Vol 20 ◽  
pp. 153303382110507
Author(s):  
Yuchao Wang ◽  
Li Li ◽  
Chunhua Xu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Adverse Reactions ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

Background: Small cell lung cancer (SCLC) is a type of highly malignant tumor. It is easy to relapse and high resistant to second-line chemotherapy. There is not a standard plan for third-line and subsequent-line treatment, hence the current study aimed to explore the performance of nanoparticle albumin bound paclitaxel (Nab-P) in the third-line treatment of recurrent SCLC. Methods: A retrospective analysis of pathologically confirmed third-line SCLC patients was conducted to observe the efficacy and adverse reactions of Nab-P treatment. Results: Among the 37 SCLC patients included in the study, objective response rate was 24.32%, and disease control rate was 81.08%. The main adverse reactions were gastrointestinal reactions, bone marrow suppression, muscle and joint aches and fatigue. Adverse reactions ≥ level 3 included leukopenia & neutropenia (24.32%), thrombocytopenia (5.41%) and anemia (2.70%). Conclusions: As a single-agent third-line treatment for patients with relapsed SCLC, Nab-P was effective and safe.

Apatinib plus icotinib in treating advanced non-small-cell lung cancer after icotinib treatment failure.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20528-e20528
Author(s):  
Jianping Xu ◽  
Xiaoyan Liu ◽  
Sheng Yang ◽  
Xiangru Zhang ◽  
Yuankai Shi
Keyword(s):  
Lung Cancer ◽  
Treatment Failure ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Toxic Effects ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Third Line ◽  
Third Line Treatment

e20528 Background: Icotinib, a small-molecule EGFR TKI, has been approved as the first-line therapy for treating advanced non-small-cell lung cancer (NSCLC) in China. However, treatment failures frequently occurred in NSCLC patients with EGFR-sensitizing mutations. A phase II clinical trial has reported the beneficial survival of apatinib, a new small-molecular VEGFR TKI, in treating NSCLC (Zhang et al. 2012 ASCO, 7548). This retrospective study tried to investigate the efficacy and safety of apatinib plus icotinib as second- or third-line treatment in patients with advanced NSCLC. Methods: This study comprised 27 patients diagnosed with advanced NSCLC and treated with icotinib and apatinib as the second- or third-line therapy. Patients received oral icotinib (125 mg, tid), alone initially. When disease progressed, they received icotinib plus apatinib (500 mg, qd, orally). Treatment was continued until disease progression or unacceptable toxic effects. Efficacy was evaluated based on RECIST version 1.0 and toxic effects were assessed using the NCI-CTC version 2.0. Results: Followed up to December, 2016, the median time of apatinib treatment was 7.47 months, and 8 of 27 patients were dead. The median overall survival had not reached and the median progression-free survival (PFS) was 5.33 months (95% CI 3.63-7.03 months). Moreover, the objective response rate (ORR) was 11.1% and the disease control rate (DCR) was 81.5%. Fourteen patients received icotinib and apatinib as the second-line treatment, and the RR and DCR were 7.1% and 78.6%. The remaining 13 patients received drugs as the third-line treatment, with an ORR and a DCR of 15.4% and 84.6%. Additionally, 11 patients experienced icotinib monotherapy failure within 6 months with median PFS of 7.37 months (95% CI 4.17-8.57 months) and 16 patients experienced icotinib monotherapy failure after 6 months with median PFS of 2.60 months (95% CI 0.00-8.54 months). The common drug-related toxic effects included hypertension (44.4%), fatigue (37.0%) and hand-foot syndromes (18.5%). Conclusions: Apatinib plus icotinib is efficacious in treating patients with advanced NSCLC after icotinib treatment failure, with acceptable toxic effects.

Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer

2013 ◽  
Vol 24 (7) ◽  
pp. 731-735 ◽  
Author(s):  
Sukhmani K. Padda ◽  
Laveena Chhatwani ◽  
Lisa Zhou ◽  
Charlotte D. Jacobs ◽  
Arturo Lopez-Anaya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Pharmacokinetic Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

scholarly journals Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer

2021 ◽  
pp. 1-1
Author(s):  
Caitlin Smare ◽  
Kiran Dave ◽  
Ariadna Juarez-Garcia ◽  
Pranav Abraham ◽  
John R. Penrod ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

Anlotinib combined with s-1 in the third-line or later-line treatment of stage IV non-small cell lung cancer: Study for phase II clinical trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21115-e21115
Author(s):  
Xiyue Yang ◽  
Xiaobo Du
Keyword(s):  
Lung Cancer ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Free Survival ◽  
The Third ◽  
Third Line ◽  
Third Line Treatment

e21115 Background: At present, for stage IV non-small-cell lung cancer (NSCLC), after the failure of second-line treatment, the effective rate of third-line treatment is not very well. We designed this study to evaluate the efficacy and safety of anlotinib combined with S-1 as a third-line treatment for patients with stage IV NSCLC. Methods: According to the inclusion and exclusion criteria, 29 patients will be treated with anlotinib plus S-1 based on Simon’s optimal two-stage design.They will undergo computed tomography (CT) every two cycles to assess the therapeutic effect according to RECIST.If the efficacy is assessed as SD, PR, CR after six cycles, anlotinib will be maintained until disease progression or death. Statistical analysis of the data will be conducted using SPSS (version 22.0).The primary endpoint is the objective response rate (ORR). The secondary endpoints are disease control rate(DCR),progression-free survival(PFS), overall survival(OS), and safety. Results: Between Jan 10, 2019, and Oct 31, 2020, a total of 29 patients were enrolled for treatment.At data cutoff (Jan 11, 2021),27(93.1%) patients had discontinued the study, and 2 (6.9%) patients were still receiving treatment. The median follow-up time was 11.2 months (IQR 8.2-20.1). Objective responses were achieved in 11 (37.9%; 95%CI 20.7-57.7) of 29 patients in the intention-to-treat population,which reached this trial’s primary endpoint. Disease control was achieved in 18 patients (62.1%; 95%CI 42.3-79.3);The median overall survival was 16.7months (95%CI 14.9-18.6);the median progression-free survival was 5.8 months (95% CI 2.9-8.7). The most common grade 3 adverse events were Gastrointestinal reactions (3[10.3%]),Fatigue (2[6.9%]), and Hypertension (2 [6.9%]).No grade 4 treatment-related adverse events, or treatment-related deaths occurred. Conclusions: The combination of anlotinib with S-1 in the third-line or later-line treatment of stage IV NSCLC shows promising anti-tumour activity and manageable toxicities in patients with NSCLC, and further study in phase 3 trials will be planned in the future. Clinical trial information: ChiCTR1900020948.

Key concerns and symptoms of patients undergoing second- and third-line treatment for non-small cell lung cancer: Findings from a patient interview study.

2012 ◽  
Vol 30 (34_suppl) ◽  
pp. 63-63
Author(s):  
Susan Magasi ◽  
Karen Kaiser ◽  
Rajiv Mallick ◽  
David Cella
Keyword(s):  
Lung Cancer ◽  
Coping Strategies ◽  
Advanced Nsclc ◽  
Interview Study ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Third Line ◽  
And Coping ◽  
Third Line Treatment

63 Background: Understanding key concerns and symptoms of patients undergoing cancer treatment is important for characterizing drug treatment benefit as well as developing appropriate psychosocial support interventions. The purpose of this interview study of patients undergoing second and third line therapy for non-small cell lung cancer (NSCLC) was to characterize their physiological, especially pulmonary, symptoms, functional impacts, emotional distress, health-related quality of life (HRQOL), and coping strategies. Methods: Semi-structured thematic interviews with 20 patients in second and third line treatment for advanced NSCLC. Interviews included open elicitation of NSCLC symptoms, their functional impact, and coping strategies. Results: Mean age was 62 years (range 30-79); 80% of patients had non-squamous histology, and 25% had co-morbid COPD. Patients described a range of core symptom experiences, severity, functional impacts, and coping strategies. Shortness of breath (reported by 16/20, 13/20 rated as very important), cough (reported by 14/20, 10/20 rated as very important), and chest tightness (reported by 15/20, 9/20 rated as very important) emerged as key pulmonary symptoms. Ninety percent (18/20) of patients reported tiredness or fatigue, mostly as “very important.” A quarter (5/20) of the patients reported having no pulmonary symptoms. The symptom importance ratings were influenced by the symptom’s impact on valued roles and responsibilities. Patients reported diverse coping strategies including breaking down activities into manageable tasks, priority setting, using physical assistance, emotional support, and adoption of diet/exercise changes. Conclusions: Findings from this interview study of patients receiving second and third line treatment for advanced NSCLC reveal the importance and relevance of core physiological, especially pulmonary, symptoms in characterizing the benefits of drug therapies. These findings offer insights to the patient education and psychosocial interventions that are likely to enhance patients’ HRQOL.

Sign in / Sign up

Export Citation Format

Share Document